[go: up one dir, main page]

CA2250029A1 - Immunotherapie cellulaire - Google Patents

Immunotherapie cellulaire Download PDF

Info

Publication number
CA2250029A1
CA2250029A1 CA002250029A CA2250029A CA2250029A1 CA 2250029 A1 CA2250029 A1 CA 2250029A1 CA 002250029 A CA002250029 A CA 002250029A CA 2250029 A CA2250029 A CA 2250029A CA 2250029 A1 CA2250029 A1 CA 2250029A1
Authority
CA
Canada
Prior art keywords
hiv
cells
serum
virus
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002250029A
Other languages
English (en)
Inventor
Richard G. Olsen
John L. Ridihalgh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cira Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2250029A1 publication Critical patent/CA2250029A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0651—Lymph nodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne, dans son ensemble, une nouvelle façon de considérer la thérapie par cellule d'adoption de l'infection par le VIH, thérapie qui tire profit de la réponse immunitaire cellulaire potentiellement efficace se développant initialement chez les individus infectés par le VIH. L'invention concerne également, de façon plus spécifique, un procédé de préparation de cellules destinées au traitement de patients atteint du VIH. Ce procédé qui consiste à prélever chez des patients infectés par le VIH des ganglions lymphatiques, consiste ensuite à provoquer l'expension de cellules productrices de cytokine issues de ces ganglions en soumettant ces cellules à stimulation mitogène en milieu asérique. L'agent thérapeutique ainsi obtenu permet de traiter des patients atteints du VIH. Cet agent est constitué d'un excipient admis en pharmacie et, comme principe actif, de cellules productrices de cytokine produites lors de l'opération consistant à provoquer l'expansion de ces cellules en soumettant à stimulation mitogène en milieu asérique, des cellules productrices de cytokine issues des ganglions lymphatiques prélevés chez des patients atteints du VIH. L'invention concerne enfin pour le traitement de patients atteints du VIH, une thérapie consistant en l'administration au patient d'une quantité suffisante de l'agent thérapeutique de l'invention. L'invention permet ainsi, non seulement de bloquer la réplication du VIH tel qu'on peut l'apprécier au niveau des réductions de charge virale que présentent les patients traités selon la thérapie de l'invention, mais également d'induire un effet de restauration immunitaire chez les patients atteints du VIH.
CA002250029A 1996-02-21 1997-02-20 Immunotherapie cellulaire Abandoned CA2250029A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60472896A 1996-02-21 1996-02-21
US604,728 1996-02-21

Publications (1)

Publication Number Publication Date
CA2250029A1 true CA2250029A1 (fr) 1997-08-28

Family

ID=24420785

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002250029A Abandoned CA2250029A1 (fr) 1996-02-21 1997-02-20 Immunotherapie cellulaire

Country Status (4)

Country Link
EP (1) EP0889693A1 (fr)
AU (1) AU727865B2 (fr)
CA (1) CA2250029A1 (fr)
WO (1) WO1997030590A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032841A2 (fr) * 1999-10-29 2001-05-10 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Methode de differentiation in vitro de lymphocytes t generes a partir de cellules souches cd34?+¿

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7873187A (en) * 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes

Also Published As

Publication number Publication date
EP0889693A1 (fr) 1999-01-13
AU2189897A (en) 1997-09-10
AU727865B2 (en) 2001-01-04
WO1997030590A1 (fr) 1997-08-28

Similar Documents

Publication Publication Date Title
Appay et al. HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function
Wang et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale
Walker et al. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults
Vánky et al. Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor.
AU2003261546B2 (en) A cell therapy method for the treatment of tumors
Liu et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas
US20150203886A1 (en) Method for Cloning T Cell Receptor
JP6073417B2 (ja) 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
US20040219168A1 (en) Method for generating highly active human dendritic cells from monocytes
Whiteside et al. Generation and characterization of ex vivo propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus
RU2391401C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
CA2326378A1 (fr) Developpement ex vivo efficace de lymphocytes t a cd4+ et cd8+ a partir de sujets infectes par le vih
Feron et al. Characterization of Toxoplasma gondii–specific T cells recovered from vitreous fluid of patients with ocular toxoplasmosis
JP2024538258A (ja) 高機能性自己幹由来のｔ細胞免疫療法
Szabolcs et al. Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin
Fiorentini et al. Generation of CD28− cells from long-term-stimulated CD8+ CD28+ T cells: a possible mechanism accounting for the increased number of CD8+ CD28− T cells in HIV-1-infected patients
CA2250029A1 (fr) Immunotherapie cellulaire
EP0460065B1 (fr) Procede de generation de lymphocytes cd4 proliferatifs
Onlamoon et al. Influence of cell isolation method on the optimization of CD4+ T cell expansion using anti-CD3/CD28 coated beads
SØNDERGAARD et al. Proliferative and cytotoxic capabilities of CD16+ CD56‐and CD16±CD56+ natural killer cells
Hammer et al. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety
US20020064874A1 (en) Method for obtaining specific T-lymphocytes, and for identifying unknown epitopes
JOBE et al. Proviral load and immune function in blood and lymph node during HIV‐1 and HIV‐2 infection
Daniel et al. CD8+ Lymphocyte Decrease in HIV Disease: Association with Anti‐CD4+ but Not with Anti‐CD8+ Lymphocyte Autoantibodies
Blakeslee et al. Adoptive immunotherapy of feline leukemia virus infection using autologous lymph node lymphocytes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued